Free Trial
NASDAQ:NGNE

Neurogene Q3 2025 Earnings Results & Report

Neurogene logo
$25.34 +0.06 (+0.22%)
As of 03:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Neurogene beat analyst earnings expectations in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$0.99 versus the -$1.26 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
9:30 AM ET

Neurogene EPS Results

Actual EPS
-$0.99
Consensus EPS
-$1.26
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Neurogene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neurogene Q3 2025 Earnings FAQ

Neurogene (NASDAQ:NGNE) reported earnings of -$0.99 per share for Q3 2025, beating the consensus estimate of -$1.26. The report was announced on Thursday, November 13, 2025.

Neurogene Earnings Headlines

Neurogene Inc. (NGNE) Latest Stock News & Headlines - Yahoo Finance
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.tc pixel
Neurogene to Participate in Upcoming Investor Conferences
See More Neurogene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neurogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neurogene and other key companies, straight to your email.

About Neurogene

Neurogene (NASDAQ:NGNE) is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options.

The company’s lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.

Founded in 2018, Neurogene is based in the United States and is led by founder and Chief Executive Officer Rachel McMinn.

View Neurogene Profile